AbbVie announced a definitive agreement to purchase a device‑manufacturing facility in Tempe, Arizona, from West Pharmaceutical Services for $112.5 million. The deal includes the facility’s production lines and the 3.5 mL on‑body injector technology that is already used in several of AbbVie’s immunology and neuroscience products.
The company will invest more than $175 million to modernize the site and create roughly 200 new jobs. The investment is part of AbbVie’s broader $10 billion commitment to U.S. manufacturing over the next decade, aimed at reducing reliance on external suppliers and strengthening supply‑chain resilience for its core therapeutic areas.
The acquisition is strategically positioned to support AbbVie’s growing immunology and neuroscience pipelines. By adding a dedicated injector platform, the company can scale production of current drugs and accelerate the launch of next‑generation therapies that rely on precise, on‑body delivery. The move also aligns with AbbVie’s focus on high‑margin, high‑growth segments and its goal of maintaining a robust domestic manufacturing footprint.
West Pharmaceutical Services is divesting the SmartDose 3.5 mL system as part of a portfolio review that shifts its focus toward larger‑dose on‑body delivery devices. The sale allows AbbVie to acquire a proven technology platform while West can reallocate capital to its strategic priorities.
CEO Robert A. Michael said, “Over the next decade, AbbVie is investing more than $10 billion in U.S. capital to broadly support innovation and expand our manufacturing capabilities. This acquisition strengthens our ability to develop and deliver next‑generation medicines that make a remarkable impact on patients’ lives.”
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.